be assessed separately but processed through a sin-
gle electronic claim; 
(7) describe how the State will select phar-
macies to be served under the TSDI; and 
(8) include the number of eligible patients to be 
served under the TSDI. 
(c) NUMBER.—The Secretary shall award grants 
under this section to not more than 5 States. 
(d) GRANT PERIOD.—A grant awarded under this 
section shall be for a period of at least 3 years. 
(e) ACCOUNTABILITY AND OVERSIGHT.—As a condi-
tion of receiving a grant under this section, a State shall 
agree to submit to the Secretary, at such time and in such 
manner as the Secretary may reasonably require, a report 
on the TSDI of the State implemented through such 
grant. Such report shall— 
(1) list the number of pharmacy locations that 
are reimbursed through the grant funds; 
(2) describe the activities undertaken by the 
State using the grant amounts, outlining the in- 
home drug disposal solutions distributed and the pa-
tient education delivered; 
(3) survey pharmacies to collect demographic 
information on participating patients, medication 
VerDate Sep 11 2014 
03:34 Jul 27, 2024
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H8570.IH
H8570
kjohnson on DSK7ZCZBW3PROD with $$_JOB
types prescribed, and the effective use of the in- 
home drug disposal systems; and 
(4) contain performance measures relating to 
the effectiveness of the grant, including changes in 
the participation rate of eligible patients and the en-
gagement with pharmacists. 
(f) DEFINITIONS.— In this section: 
(1) ELIGIBLE
PATIENTS.—The term ‘‘eligible 
patients’’ means patients receiving an opioid pre-
scription who are at risk of experiencing an opioid- 
related overdose, including such patients— 
(A) with a first-time opioid prescription; 
(B) with an acute opioid prescription pre-
scribed for a short-term illness or condition; or 
(C) that have received a change in the 
opioid dosage of an acute or chronic opioid pre-
scription. 
(2) IN-HOME DRUG DISPOSAL SYSTEM.— The 
term ‘‘in-home drug disposal system’’ means a sys-
tem of drug disposal— 
(A) that changes the physical integrity of 
the formulation of a drug; 
(B) that renders the active ingredients of 
such drug unusable for all practical purposes; 
(C) that— 
VerDate Sep 11 2014 
03:34 Jul 27, 2024
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H8570.IH
H8570
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(i) is nontoxic and nonhazardous; 
(ii) poses no threat to the consumer; 
and 
(iii) reduces drug exposure to the en-
vironment; and 
(D) that acts as a deterrent for misuse of 
drugs. 
(3) STANDARD
MEDICATION
SAFETY
EDU-
CATION.—The term ‘‘standard medication safety 
education’’ means medication safety education— 
(A) provided by a pharmacist or pharmacy 
technician to eligible patients for a duration of 
not more than 5 minutes per patient; and 
(B) that includes information relating to— 
(i) proper medication storage; 
(ii) risks associated with keeping un-
used medication in the home; 
(iii) proper in-home disposal of un-
used medication; and 
(iv) in the case of naloxone that is 
prescribed as an opioid medication, the 
proper use of such naloxone 
(4) STATE.—The term ‘‘State’’ means each of 
the several States, the District of Columbia, and any 
territory of the United States. 
VerDate Sep 11 2014 
03:34 Jul 27, 2024
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H8570.IH
H8570
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(g) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section 
$56,000,000 for the period of fiscal years 2025 through 
2029. 
Æ 
VerDate Sep 11 2014 
03:34 Jul 27, 2024
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H8570.IH
H8570
kjohnson on DSK7ZCZBW3PROD with $$_JOB